Trials / Completed
CompletedNCT00389441
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
Detailed description
Additional study details: assess safety and efficacy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG-013736 | AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2006-10-18
- Last updated
- 2013-11-25
- Results posted
- 2013-11-25
Locations
26 sites across 9 countries: United States, Canada, China, Czechia, India, Italy, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00389441. Inclusion in this directory is not an endorsement.